Company Profile

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01020Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE1919.7513.6 (+0.71 % )
PREV CLOSE (Rs.) 1906.15
OPEN PRICE (Rs.) 1907.00
BID PRICE (QTY) 1919.80 (20 )
OFFER PRICE (QTY) 1921.90 (35 )
VOLUME 2413
TODAY'S LOW / HIGH (Rs.)1895.05 1927.00
52 WK LOW / HIGH (Rs.)1162 2455.55
NSE1925.00 17.95 (+0.94 % )
PREV CLOSE(Rs.) 1907.05
OPEN PRICE (Rs.) 1871.00
BID PRICE (QTY) 1924.30 (10 )
OFFER PRICE (QTY) 1925.00 (939 )
VOLUME 66475
TODAY'S LOW / HIGH(Rs.) 1871.00 1925.00
52 WK LOW / HIGH (Rs.)1200 2460

Company News

Date Heading Details
19-Jan-2021 Board Meeting Intimation for Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended 31St December, 2020 Of The Financial Year 2020-21 IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2021 ,inter alia, to consider and approve Unaudited Financial Results for the 3rd quarter and nine months ended 31st December, 2020 of the financial year 2020-21
30-Nov-2020 Ipca Laboratories informs about disclosure <DIV align=justify><SPAN>Ipca Laboratories has informed that it has enclosed disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.</DIV><SPAN><DIV align=justify><BR></DIV><DIV align=justify><SPAN>The above information is a part of company's filings submitted to BSE.</DIV><DIV><BR></DIV>
27-Oct-2020 Ipca Laboratories to hold board meeting <p align="justify">Ipca Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 07/11/2020, to consider and take on record the Unaudited Financial Results for the 2nd quarter and half year ended 30th September, 2020 of the financial year 2020-21; and to consider declaration of Interim Dividend for the financial year 2020-21. </p><p align="justify">The above information is a part of company's filings submitted to BSE.</p>
18-Sep-2020 Ipca Laboratories informs about proceedings of 70th AGM <p align="justify">Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it has enclosed the proceedings at the 70th Annual General Meeting (AGM) of the Company held on 17th September, 2020.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
18-Sep-2020 Ipca Laboratories informs about voting results of 70th AGM <p align="justify">Pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it has enclosed the results of the voting on the proposed resolutions along with the Consolidated Report on the voting issued by Jigyasa N. Ved of Parikh &amp; Associates, Practising company Secretaries, Scrutinizer appointed for the 70th Annual General Meeting (AGM) of the Company held on 17th September, 2020. In this regard, note that all the five (5) resolutions placed before the shareholders as per the notice of the Annual General Meeting have been passed by requisite majority.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
17-Aug-2020 Ipca Laboratories in process of obtaining environmental clearance for new plant in MP <p align="justify">Ipca Laboratories is in the process of obtaining environmental clearance for setting up a new active pharmaceutical ingredients (API) manufacturing unit at Dewas, Madhya Pradesh (MP)&nbsp;with an initial capital outlay of about Rs 250 crore. The company has already acquired land for the project. Currently, it produces over 80 APIs at 12 production facilities, accounting for nearly 25 percent of its turnover.</p><p align="justify">Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company's income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.<br></p>
05-Aug-2020 Ipca Laboratories informs about conference call <p align="justify">In accordance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a Conference Call to discuss the Company's Q1 FY21 earnings and business update will be held on Tuesday, 11th August, 2020 at 11.00 hrs IST.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
02-Jul-2020 Ipca Laboratories informs about company updates <p align="justify">Further to it letters dated 21st March, 2020 and 24th June, 2020, Ipca Laboratories has informed that the US FDA through its e-mail dated 1st July, 2020 has intimated the Company that the shortage implications for Hydroxychloroquine Sulphate has changed and that it has been removed from list of drug products in shortage and therefore, the US FDA is removing the exemption given to us from the import alert for API and formulation of Hydroxychloroquine Sulphate.</p><p align="justify">The above information is a part of company's filings submitted to BSE.&nbsp;</p>
24-Jun-2020 Ipca Laboratories informs about update on USFDA <p align="justify">In furtherance to letter dated 21st March, 2020 intimating USFDA exemption from import alert for APls Chloroquine Phosphate and Hydroxycholoroquine Sulfate manufactured from Company's APls manufacturing facility situated at Ratlam (M.P), Ipca Laboratories has now informed that the USFDA vide its email dated 23rd June 2020 has communicated to the Company that shortage implications for Chloroquine Phosphate API has changed and Chloroquine Phosphate drug product is&nbsp; no&nbsp; longer in shortage and therefore, no shipment of API Chloroquine Phosphate will be excluded from the import alert. USFDA has also informed hat due to potential shortage implications and/ or medical necessity, exception to the import alert has been made for API Hydroxychloroquine Sulfate. USFDA has further informed that this exception will be re-considered if the shortage implications change.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
23-Mar-2020 Healthcare Services industry stocks trade higher on the bourses <p align="justify">Healthcare Services industry stocks were trading higher after the government approved Rs 13,760 crore package to boost production of bulk drugs, medical devices.<br></p><p align="justify">Ipca Laboratories is currently trading at Rs 1407.95, up by 36.10 points or 2.63% from its previous closing of Rs. 1371.85 on the BSE. The scrip opened at Rs. 1485.00 and has touched a high and low of Rs. 1615.70 and Rs. 1269.90 respectively. So far 38757 shares were traded on the counter.</p><p align="justify">Thyrocare Technologies is currently trading at Rs 530.00, up by 24.25 points or 4.79% from its previous closing of Rs 505.75 on the BSE. The scrip opened at Rs 519.90 and has touched a high and low of Rs. 574.00 and Rs 490.00 respectively. So far 25277 shares were traded on the counter.</p><p align="justify">Minister of State for Chemicals and Fertilisers Mansukh Mandaviya has said that the government has approved four schemes with an incentive outlay of Rs 9,940 crore and Rs 3,820 crore for bulk drugs and medical devices respectively, to boost their domestic production in the country and exports. He said the Cabinet also approved a sum of Rs 3,000 crore for the next five years for the scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks. </p><p align="justify">Mandaviya also stated that a sum of Rs 6,940 crore has been approved for the Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country. He said the PLI scheme will lead to expected incremental sales of Rs 46,400 crore and significant additional employment generation over eight years. He added that the scheme for promotion of medical device parks seeks to promote medical device parks in the country in partnership with the states. </p><p align="justify">The minister further said that a maximum grant-in-aid of Rs 100 crore per park will be provided to the states. It will have financial implications of Rs 400 crore. He noted that the PLI scheme for promoting domestic manufacturing of medical devices with financial implications of Rs 3,420 crore and the expenditure to be incurred for the schemes on promotion of medical devices will be for the next five years. </p><p align="justify"><br></p>